James Deardorff on X: ""Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease" - Hmm... 1. https://t.co/k7Ga4ja0br 2. https://t.co/5cr8gYW72s https://t.co/7NboyUVjWr" / X
Biogen's Alzheimer's Drug Gets FDA Approval, Mixed Reviews | The Scientist Magazine®
Biogen's Alzheimer's drug approved by FDA, first new therapy in nearly two decades
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year | Fierce Pharma
Biogen gives up seeking European approval for aducanumab - Drug Discovery and Development
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies | Biogen
Biogen Reverses Take on Aducanumab Trial Data | MedPage Today
Aduhelm (aducanumab) Q+A - Penn Memory Center
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
Press Releases – Page 2 – Global Alzheimer's Platform Foundation
Congressional Probe of Alzheimer's Drug Approval Finds Fault With FDA Actions | MedPage Today
With Spotlight on Alzheimer's Disease and Biogen, Competitors' Stocks Soar | BioSpace
The Science of Aging: Summer 2020 – The Science of Aging
FDA changes prescribing instructions to limit use of contentious Alzheimer's drug amid public backlash | KTLA
FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries | KFF
Biogen's Aducanumab: A Look at the Drug's History and Recent Updates | BioSpace
Early Access Programs | Biogen
Congressional Investigation into Alzheimer's Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer's Disease | Biogen
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YOZVWDX35VKEVCOQV4LDNO3ZTQ.jpg "U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day\" for patients | Reuters")
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
FDA Approval of a New Alzheimer's Drug Comes With Controversy | Smart News| Smithsonian Magazine
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
Aducanumab: New Medication FDA Approved for Alzheimer's Disease – Psychiatry Education Forum
